Financials in USD. Standardized financial statements.
A compact view of how RavenQuest BioMed Inc. turns revenue into operating income and net income.
| Metric | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.26M | $112,351 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +1018.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $455,448 | $97,697 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $801,292 | $14,654 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +63.7% | +13.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $801,292 | $656,264 | $81,458 | $82,628 | $75,895 | $105,177 | $134,054 | $110,531 | $82,122 | $91,636 |
| Operating Income? | -$17.18M | -$642,000 | -$71,475 | -$82,690 | -$75,895 | -$105,000 | -$134,000 | -$111,000 | -$82,122 | -$91,636 |
| EBITDA? | -$27.26M | -$3.15M | -$81,458 | -$76,089 | -$62,337 | $291,929 | -$369,000 | -$111,000 | -$82,122 | -$91,636 |
| Income Before Tax | -$31.05M | -$3.30M | -$81,458 | -$76,029 | -$60,567 | -$502,000 | $100,500 | -$110,000 | -$82,068 | $0 |
| Income Tax Expense | -$578,000 | $0 | $0 | $0 | $0 | -$60 | -$76 | -$25,000 | $0 | $90,705 |
| Net Income? | -$30.47M | -$3.30M | -$81,458 | -$76,029 | -$60,567 | -$502,000 | $100,500 | -$110,000 | -$82,068 | -$90,705 |
| EPS? | $-0.33 | $-0.10 | $-0.00 | $-0.00 | $-0.00 | $-0.02 | $0.00 | $-0.00 | $-0.00 | $-0.00 |
| Diluted EPS? | $-0.33 | $-0.10 | $-0.00 | $-0.00 | $-0.00 | $-0.02 | $0.00 | $-0.00 | $-0.00 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality